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Abstract
Currently, the term “melanoma associated with pregnancy” is used, implying 
the inclusion of all clinical observations of melanoma diagnosis during pregnancy 
and in the first 2 years after delivery. The management of pregnant women with 
newly diagnosed melanoma is likewise controversial, especially with regard to the 
management of women with an advanced melanoma. Thrombotic complications 
are the most common form of paraneoplastic syndrome, which largely determines 
the prognosis of the disease. The presented chapter is intended to familiarize 
practical physicians with the complexities that arise in the management of pregnant 
women with a developing metastatic disease, with questions of the progression 
of the disease during pregnancy, with the emergence of severe paraneoplastic 
complications involving secondary thrombophilia, amaranthine endocarditis, and 
widespread arterial thrombosis. The possibility of using modern antitumor drugs 
(Zelboraf) is shown. It is emphasized that in the management of such patients, 
the need for an effective team of specialists of various profiles is especially high: 
oncologists, obstetrician-gynecologists, surgeons, hematologists, anesthesiologist-
resuscitators, and US and magnetic resonance imaging (MRI) diagnostics.
Keywords: melanoma, pregnancy, secondary thrombophilia, paraneoplastic 
syndrome, vemurafenib
1. Introduction
Melanoma of the skin (lat. —melanoma, melanoma malignum) is a malignant 
tumor that results from neoplastic transformation of melanocytes—cells that 
produce various variations of melanin pigment [1]. In recent years, there has 
been an increase in the incidence of skin melanoma in Russia. Between 1998 and 
2008, the incidence rate in the Russian Federation was 38.17%, and the standard-
ized morbidity rate rose from 4.04 to 5.46 per 100,000 population. In 2008, the 
number of new cases of melanoma in the Russian Federation was 7744 people. 
Mortality from melanoma in the Russian Federation in 2008 was 3159 people and a 
standardized death rate of 2.23 people per 100,000 population [2]. Approximately 
one-third of women diagnosed with melanoma are of childbearing age, and a 2015 
Swedish population-based cancer registry study found that melanoma was the 
most common malignancy in pregnancy [3]. Melanoma is a significant proportion 
of all tumors diagnosed during pregnancy, and this figure is up to 25% among all 
tumor diseases during gestation. There is continuing controversy concerning the 
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prognosis of women diagnosed with melanoma during pregnancy. Initial concerns 
about pregnancy’s impact on prognosis in women diagnosed with melanoma date 
back to case reports from the 1950s. These reports suggested that pregnancy might 
lead to transformation of nevi into melanomas, increase the growth rate of existing 
melanomas, and cause localized melanomas to metastasize [4]. Subsequently, mul-
tiple observations seemed to support the argument that melanoma is a hormonally 
responsive malignancy: changes in skin pigmentation during pregnancy, detection 
of hormone receptors on some melanomas using older technology, a higher inci-
dence of melanoma after puberty, and relative immunosuppression during preg-
nancy. The management of women diagnosed with melanoma during pregnancy is 
likewise controversial, particularly concerning sentinel lymph node biopsy (SLNB) 
and decisions about the management of the patient with nodal or metastatic 
disease [5]. Multiple studies have looked at the relationship between pregnancy and 
cutaneous melanoma. Factors limiting the interpretation of the literature include 
the following:
• Many of the case series prior to the 1980s did not account for the most 
important prognostic factors, such as depth of tumor or stage of disease. 
Subsequently, there have been a number of small case-control studies and 
large population-based cohort studies. While the case-control studies have 
the advantage of including important prognostic factors, the small numbers 
of patients included are an important limitation. Conversely, the larger cohort 
studies lack complete data on staging and Breslow depth.
• Some of the larger studies do not distinguish between diagnosis of melanoma 
during pregnancy and diagnosis during the postpartum period. Such studies 
refer to these patients as having pregnancy-associated melanoma (PAM). The 
definition of PAM varies in different studies and ranges from diagnosis during 
pregnancy to diagnosis up to 5 years after delivery [6].
• There is significant variability in the techniques and quality of the statistical 
analysis of the data between studies and in the presence of age-matched nonpreg-
nant control groups, as well as a lack of consideration of important confounding 
factors, including but not limited to age, anatomic site of lesion, sun exposure or 
season at time of diagnosis, depth of the melanoma, the absence or presence of 
ulceration, and the presence as well as number of mitoses per mm2 [2].
2. Definition
Deciding on the role of pregnancy in the development of melanoma is impor-
tant, as more women are planning a pregnancy from 30 to 40 years, and an increase 
in the number of melanoma diagnoses during fetal growth is expected [3, 4]. 
Currently, the term “melanoma associated with pregnancy” is used, implying the 
inclusion of all clinical observations of the diagnosis of melanoma during preg-
nancy and in the first 2 years after delivery [5].
2.1 Diagnosis prior to pregnancy
Few studies have addressed the impact on prognosis when melanoma is diag-
nosed before a woman becomes pregnant, but based upon the available data, 
there does not appear to be an effect on prognosis. In a large Swedish retrospective 
cohort study [6], 966 women who had pregnancies after a diagnosis of a primary 
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melanoma were compared with 4567 women who did not become pregnant after 
diagnosis. After adjustment for Breslow depth, tumor site, Clark level, and age, 
pregnancy did not significantly affect survival (HR 0.58, 95% CI 0.32–1.05). For 
patients with a history of melanoma and multiple dysplastic nevi, we suggest more 
frequent dermatology examinations during pregnancy [7].
2.2 Diagnosis during pregnancy
Most of the multiple small controlled studies and large population-based 
cohort studies [6] do not show a negative influence of pregnancy on survival [2]. 
In a review of 10 case-control studies that included 185 women diagnosed with 
melanoma during pregnancy and 5348 women of the same childbearing age who 
were diagnosed with melanoma but were not pregnant, pregnancy did not have 
an impact on survival and did not increase the risk of a second melanoma [8]. The 
higher the parity and the younger the age of the mother at her first delivery, the 
lower the risk of melanoma. Thus, the authors concluded that there was no reason 
for physicians to recommend deferral of subsequent pregnancies in women who 
have been diagnosed with a stage I melanoma during a previous pregnancy [1]. 
A controversial study is a single-institution study that compared 41 women diag-
nosed with PAM with a control group of women of childbearing age who were not 
pregnant within 1 year of diagnosis [9]. PAM was defined as melanoma diagnosis 
either during pregnancy or within 1 year after delivery. After adjustment for stage, 
age, and location, the PAM group showed a five-, seven-, and ninefold increase in 
mortality, metastasis, and recurrence, respectively, when compared with controls.
2.3 Diagnosis postpartum
Multiple large population-based cohort studies [3, 10] and one small controlled 
study have generally found no influence on prognosis when melanoma is diagnosed 
up to 5 years following delivery, except for one study that observed an enhanced 
risk of death from melanoma in the first year postpartum, which may be due to 
delayed diagnosis during pregnancy. A large retrospective English study that linked 
data from a national cancer registry and hospital discharge data evaluated patients 
diagnosed with melanoma up to 5 years postpartum [10]. There was a significant 
increased death rate in the first year after delivery (HR 1.92, 95% CI 1.32–2.79) but 
not in the four subsequent years postpartum. Another study found a lower inci-
dence of melanoma diagnosed during pregnancy than expected compared with the 
first 6 months postpartum [2]. The spike in melanoma diagnosis and death in the 
early postpartum period may be caused by a delay in diagnosis.
3. Classification
The eighth edition of the American Joint Committee on Cancer (AJCC) tumor, 
node, and metastasis (TNM) staging system is based upon an evaluation of the pri-
mary tumor, the regional lymph nodes and lymphatic drainage, and the presence or 
absence of distant metastases. The information from TNM staging is then combined 
to classify patients into AJCC prognostic stage groups. There are four major growth 
patterns of melanoma: lentigo maligna, nodular, superficial spreading, and acral 
lentiginous. In an observational study of close to 120,000 patients with melanoma, 
nodular melanoma was an independent risk factor for death, after controlling 
for thickness, ulceration, and stage [11]. Nevertheless, the eighth edition of the 
American Joint Committee on Cancer tumor, node, and metastasis staging system, 
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which relies upon the primary tumor thickness and other features, involvement of 
regional lymph nodes, and presence or absence of distant metastases, should be 
used to stage melanomas of any growth pattern. Most melanomas arise as superfi-
cial tumors that are confined to the epidermis, where they may remain for several 
to many years. During this stage, known as the horizontal or “radial” growth phase, 
the melanoma is almost always curable by surgical excision alone. Melanomas that 
infiltrate into the dermis are considered to be in a “vertical” growth phase and have 
metastatic or “tumorigenic” potential. Nodular melanomas have no identifiable 
radial growth or in situ phase and appear to enter the vertical growth phase from 
their inception, resulting in thicker tumors at diagnosis.
In order to determine the stage of melanoma and, consequently, the physician’s 
tactics and therapy regimen, it is common to use the levels of Clarke’s invasion 
(1969), as well as the international TNM system. The level of invasion by Clark 
allows you to determine the number of layers of the epidermis affected by mela-
noma at the time of its detection. The system for determining the level of invasion 
according to Clark is historically the first system for determining the stage of inva-
sion of melanoma into the epidermis, according to which tumors are divided into 
five stages (Table 1).
The depth of invasion is determined by the stages of Breslow (1970) [12]:
• Thin: the depth of invasion is less than 0.75 mm.
• Intermediate: the depth of invasion is 0.76–3.99 mm.
• Thick (deep): the depth of invasion is more than 4 mm.
After establishing the categories T, N, and M, they are grouped to determine the 
stage of the disease, which is expressed in Roman numerals from I to IV.
Stage 0: melanoma in situ (Clark level I), 99.9% survival rate
Stage I/II: invasive melanoma, survival rate of 89–95%
T1a: primary tumor thickness less than 1.0 mm, without ulceration <1/mm2
T1b: primary tumor thickness less than 1.0 mm, with ulceration ≥1/mm2
T2a: thickness of the primary tumor 1.01–2.0 mm, without ulceration.
Stage II: high-risk melanoma, 45–79% survival
T2b: primary tumor thickness 1.01–2.0 mm, with ulceration
T3a: primary tumor thickness 2.01–4.0 mm, without ulceration
T3b: primary tumor thickness 2.01–4.0 mm, with ulceration
T4a: thickness of the primary tumor is more than 4.0 mm, without ulcer-
ationT4b: thickness of the primary tumor is more than 4.0 mm, with ulceration.
Stage III: regional metastases, survival 24–70%
N1: single lymph node affected
N2: from two to three affected lymph nodes or regional metastases of the skin
N3: four affected lymph nodes or one lymph node with regional skin metastases.
Stage IV: distant metastases, survival rate of 7–19%
M1a: distant skin metastases, normal LDH.
M1b: lung metastases, normal LDH.
M1c: other distant metastases or any distant metastases with elevated LDH [6, 8].
The American Joint Committee on Cancer recently published its eighth edi-
tion of staging criteria, which went into effect as of 1 January, 2018. The impact of 
Breslow depth and mitoses has been adjusted in the new AJCC staging. The most 
significant change is that all tumors with a Breslow depth of 0.8–1.0 mm are now 
staged as T1b. Non-ulcerated tumors with a Breslow depth of <0.7 mm are still 
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classified as T1a. In addition, Breslow depth is now reported to the nearest 10th 
decimal place. Therefore, with rounding, T1b tumors encompass 0.75–1.04 mm or 
any ulcerated tumor of <0.7 mm [8]. Mitoses are no longer part of the criteria to 
upstage from T1a to T1b. There were no changes to T2–T4 staging. The clinical stage 
groups were not altered; T1a is still stage 1A, and T1b is still stage 1B [8].
4. Etiopathogenesis
One of the theories supporting the possible effect of pregnancy on tumor 
transformation is that pregnancy is considered a state of immunodeficiency, 
necessary to prevent the development of an immune response to fetal antigens. 
Although the exact mechanism by which tolerance to the fetus development 
is unclear, several immunological changes may allow the fetus to develop and 
grow. During pregnancy, the level of granulocytes increases, the number of 
monocytes remains unchanged, and a significant decrease in lymphocytes is also 
observed. T-lymphocyte activity is suppressed, and a disruption in the produc-
tion of interleukins and interferon-G is demonstrated. However, the function of 
B-lymphocytes remains unchanged, and therefore the immune system during 
pregnancy is described as a bias toward the humoral immunity, which is more 
responsible for the formation of antibodies. This change in the balance of Th1 
and Th2 cells is similar to the immunological state of patients with oncology [6]. 
Another possible mechanism of fetal tolerance involves the secretion of protein 
B7-H1 (CD274) by trophoblast cells; the B7-H1 protein induces apoptosis of 
activated T cells. This is important because it is also reported that melanoma can 
elude immune surveillance and secrete B7-H1. The combined secretion of B7-H1 
can lead to the fact that melanoma during pregnancy grows and metastasizes 
more quickly. In addition, it was found that human leukocyte antigen HLA-G is 
expressed by placental trophoblast cells. Recent studies have shown the role of 
mutations BRAF V600E in 50% of all skin melanoma development [9]. The fact 
is that under the influence of excessive UV irradiation, there is a V600 mutation 
consisting of replacing valine with leucine (V600L), lysine (V600K), or glutamic 
acid (V600E) in the 600th position, which serves as a signal for the onset of 
neoplastic transformation. An important role in determining the prognosis is also 
the age and gender of the patient (women have a better prognosis), tumor local-
ization, lymph node involvement, and the presence of tumor suppressor genes 
Clark stage Characteristics Patient 
survival
The level of 
invasion I
All tumor cells are in the epidermis and do not reach the basal 
membrane
98–100%
The level of 
invasion II
Tumor cells infiltrate the papillary layer of the dermis 72–96%
The level of 
invasion III
The tumor reaches the border between the papillary and reticular 
dermis. The tumor enters the phase of vertical growth
46–90%
The level of 
invasion IV
Tumor cells are detected in the reticular layer of the dermis 31–67%
The level of 
invasion V
The tumor invades in the fatty tissue 12–48%
Table 1. 
Microscopic melanomas by Clark (1969) [7].
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(CDKN2A, CDK4) and proliferative markers (PCNA, Ki-67) and the presence 
of thromboses and thromboembolism. Thrombotic complications are the most 
common complications of paraneoplastic syndrome, manifested by arterial and 
venous thrombotic occlusions, migrating thrombophlebitis, pulmonary embo-
lism, palpable non-bacterial thromboendocarditis, paradoxical bleeding, and 
thrombotic microangiopathy. Clinically, venous thromboembolism and malignant 
neoplasm have two main manifestations: firstly, thrombosis can be the only clinical 
manifestation of the tumor process, and secondly, in patients with cancer at all 
stages of the disease, thrombosis may develop [7, 10, 11]. Approximately 10% 
of melanomas are familial. Among subjects from melanoma families, defined as 
kindreds in which melanoma occurred in two or more blood relatives, the likeli-
hood of developing melanoma is even greater among those family members who 
have dysplastic nevi. In a subset of these kindreds, the apparent familial pattern 
of inheritance may be attributable to clustering of sporadic cases in families who 
share common heavy sun exposure and susceptible skin type, making genetic 
analysis and risk stratification more challenging. This concept is substantiated 
by studies in which CDKN2A mutation status, sun exposure, and prevalence of 
dysplastic/benign nevi influence melanoma risk in families unselected for family 
history as well as melanoma-prone families.
5. Factors of the risk and clinical picture
The clinical recognition of melanoma, and in particular of early melanoma, 
may be challenging, even for the most experienced dermatologist. It has been 
estimated that the sensitivity of the clinical diagnosis of experienced dermatologists 
is approximately 70% [13]. However, the use of diagnostic aids such as dermoscopy, 
which requires some training, may greatly improve the sensitivity and specificity of 
the clinical diagnosis [14].
5.1 History and risk factors
Key questions that should be asked to patients presenting with a lesion that is of 
concern or for a general examination of their nevi include:
• When was the lesion (or a change in a preexisting lesion) first noticed?
• Does the patient have a personal or family history of melanoma or other skin 
cancers?
• Does the patient have a history of excessive sun exposure and/or tanning bed use?
• Did the patient suffer severe sunburns during childhood or teenage years?
• Does the patient have a cancer-prone syndrome (e.g., familial atypical multiple 
mole-melanoma syndrome or xeroderma pigmentosum)?
• Is the patient immunosuppressed?
• Did the patient receive prolonged psoralen plus ultraviolet A (PUVA) therapy?
The patient’s phenotypic features associated with an increased risk of melanoma 
should also be assessed. They include:
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• fair-complexioned phototype
• red or blond hair
• light eye color
• presence of a large number (>50) of melanocytic nevi (common nevi)
• presence of atypical melanocytic nevi (benign nevi that clinically share some of 
the clinical features of melanoma, such as large diameter, irregular borders, and 
multiple colors)
Clinicians assess the probability that a pigmented lesion is a melanoma using a 
complex cognitive process that includes a combination of the following steps: visual 
analysis and pattern recognition, comparative analysis of nevus patterns in an 
individual patient, and dynamic analysis:
• Visual analysis and pattern recognition typically assess whether a given pig-
mented lesion has one or more features that may suggest melanoma, includ-
ing asymmetry, irregular borders, variegated color, and diameter > 6 mm. 
These features have been included in the widely adopted ABCDE checklist: 
Asymmetry (if a lesion is bisected, one half is not identical to the other half), 
Border irregularities, Color variegation (the presence of multiple shades of red, 
blue, black, gray, or white), Diameter ≥ 6 mm, and Evolution (a lesion that is 
changing in size, shape, or color or a new lesion, a clinical prediction rule that 
was devised to help clinicians and laypeople identify suspicious lesions).
• The intrapatient comparative analysis uses the so-called “ugly duckling” sign, 
which refers to the presence of a single lesion that does not match the patient’s 
nevus phenotype (the so-called signature nevus).
• A history of change in size, color, or shape of a preexisting melanocytic lesion 
(the “E” for “evolution” in the ABCDE checklist) is the most important clinical 
criterion for the diagnosis of melanoma. A change can be noted by the patient 
or documented by comparison of serial clinical or dermoscopic images.
6. Management of melanoma during pregnancy
The evaluation and management of the pregnant woman are similar to that of 
the nonpregnant woman and are based upon the stage of disease. However, there 
are potential concerns that arise even in the initial biopsy of suspected melanoma. 
As the stage of disease becomes more advanced, evaluation and management 
decisions become more complex in order to ensure safety of the mother and the 
fetus [1, 2].
A changing pigmented lesion during pregnancy that is clinically and dermato-
scopically of concern as a possible melanoma should be biopsied immediately, as it 
would be in a nonpregnant patient. Excisional biopsy is the optimal way to evaluate 
a primary cutaneous melanoma. If the pregnant patient is considered a candidate 
for sentinel lymph node biopsy, there is controversy about the technique and timing 
of the procedure. In the case of a woman with advanced melanoma, imaging studies 
may be considered. According to a Committee Opinion Summary published by 
the American College of Obstetrics and Gynecologists’ Committee on Obstetric 
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Practice, chest radiograph with appropriate shielding, ultrasonography, and mag-
netic resonance imaging (MRI; preferably without gadolinium) are the techniques 
of choice for imaging of the pregnant female [15]. In addition, studies such as other 
radiography, computed tomography (CT) scan (without contrast), and nuclear 
medicine imaging studies can be utilized since they are typically administered at 
doses that do not lead to fetal harm.
Some studies have suggested that melanomas diagnosed during pregnancy are 
more often of greater Breslow depth [16], but a larger proportion of studies have not 
observed a significant difference. Likewise, a retrospective review analyzed both 
clinical and pathologic characteristics of 34 melanomas diagnosed during preg-
nancy and up to 1 year after delivery and compared these with melanomas from 
age- and disease-matched controls. There was no significant difference in Breslow 
depth, ulceration, mitotic rate, stage of disease, anatomic location of the primary 
tumor, histologic subtype, Clark level, regression, necrosis, or vascular invasion [2].
While melanoma is the most common cancer to metastasize to the fetus, metas-
tasis across the placenta to the fetus is rare and is only observed in women with 
widely metastatic disease [17–19] (Figure 1). Even if placental involvement with 
melanoma is identified, it has been estimated that the fetus is affected in only 25% 
of these cases. In cases of maternal advanced disease, it is important to alert the 
pathologist to perform meticulous sectioning of the placenta since many sections 
may be needed to detect small foci of melanoma.
The general approach to the treatment of pregnancy-associated melanoma is 
based upon the same prognostic factors as for nonpregnant woman. Melanoma 
diagnosed during pregnancy is a rare clinical case presentation which must be 
mastered. In the absence of guidelines for this clinical challenge, we performed a 
review of the literature and provide a practical guideline on how to manage such 
rare clinical cases based on our clinical experience. Expecting mothers require 
adequate counseling and explanation of all therapeutic options as they take respon-
sibility for more than their own lives. However, they should be guided through the 
process of diagnostic and therapeutic measures in a potentially life-threatening 
situation. Pregnancy itself is no reason to withhold any type of necessary melanoma 
surgery. Perioperative management, however, requires certain adjustments in order 
to comply with this special situation. If indicated, even adjuvant and palliative 
systemic therapies need to be given to the patient, but they also have to be adapted 
to the specific circumstances as data is still sparse, especially for the new first- and 
second-line therapies with antibodies and targeted molecules.
Management becomes more complex once the need for SLNB is established or 
if the patient has more advanced disease and should be individualized. In advanced 
melanoma, the newest agents, such as BRAF inhibitors (vemurafenib and dab-
rafenib) and checkpoint inhibitors [nivolumab and ipilimumab (anti-programed 
cell death-1 and anti-CTLA, respectively)], may be teratogenic [17–21]. The 
FDA-approved patient labeling recommends avoidance of pregnancy and lactation 
during BRAF inhibitor therapy and up to 2 weeks after the last dose, during ipilim-
umab therapy and up to 3 months after the last dose, and during nivolumab therapy 
and up to 5 months after the last dose.
The patient with a thin melanoma with excellent prognosis need not delay 
future pregnancies or avoid the use of oral contraceptives or hormone replacement 
therapy, if the latter are indicated.
The combination of pregnancy and the high stage of melanoma are a danger-
ous condition requiring careful risk assessment by the obstetrician-gynecologist 
and oncologist. Earlier, women with melanoma III and IV stages were artificially 
interrupted by pregnancy according to medical indications. However, at present, in 
relation to risk stratification and pregnancy management in women with melanoma 
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associated with pregnancy, there is a view that therapeutic approaches are almost 
the same as those of nonpregnant ones and are determined by the stage of the 
disease. For patients with a history of melanoma and multiple dysplastic nevi, a 
more frequent dermatological examination during pregnancy is suggested. With 
regard to recommendations for the implementation of the reproductive function, 
it is shown that a future pregnancy should not be delayed in a woman with a thin 
localized melanoma with a favorable prognosis. For patients with progressive 
Figure 1. 
Histological examination of biopsy (intraoperative) material (hematoxylin-eosin staining). The material is 
represented by a lymph node located among adipose tissue with tumor metastasis (a), which has the structure 
of epithelioid cell melanoma with a high content of pigment (b). The tumor totally replaces the tissue of the 
lymph node with the germination of the capsule (c).
Cutaneous Melanoma
10
disease, it is recommended to wait at least 2–3 years before pregnancy, since during 
this time interval relapses are most likely [13, 15, 22]. However, this issue should 
be considered individually in each specific observation, since a woman of late 
reproductive age may be concerned about the implementation of reproduction in 
the event of a pregnancy failure. The problem becomes even more controversial in 
a woman with a common form of the disease, because her life expectancy remains 
unclear. Decision-making becomes much more complex in the woman with a more 
uncertain prognosis where a delay in future pregnancy may be considered, but this 
should be evaluated on a case-by-case basis.
Author details
Ignatko Irina Vladimirovna* and Strizhakov Alexander Nikolaevich
Federal State Autonomous Educational Institution of Higher Education 
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of 
the Russian Federation, Sechenov University, Moscow, Russia
*Address all correspondence to: iradocent@mail.ru
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
11
Melanoma and Pregnancy: Risks, Current, and Forecast
DOI: http://dx.doi.org/10.5772/intechopen.86928
[1] Jhaveri MB, Driscoll MS, Grant-
Kels JM. Melanoma in pregnancy. 
Clinical Obstetrics and Gynecology. 
2011;54(4):537-545. DOI: 10.1097/
GRF.0b013e318236e18b
[2] Driscoll MS, Stein JA, Grant-Kels 
JM. Melanoma in pregnancy. UpToDate. 
2016
[3] Andersson TM, Johansson AL, 
Fredriksson I, Lambe M. Cancer during 
pregnancy and the postpartum period: 
A population-based study. Cancer. 
2015;121(12):2072-2077
[4] Pack GT, Scharnagel IM. The 
prognosis for malignant melanoma 
in the pregnant woman. Cancer. 
1951;4(2):324
[5] Ribero S, Longo C, Dika E, Fortes C, 
Pasquali S, Nagore E, et al. Pregnancy 
and melanoma: A European-wide survey 
to assess current management and a 
critical literature overview. Journal of 
the European Academy of Dermatology 
and Venereology. 2017;31(1):65
[6] Lens MB, Rosdahl I, Ahlbom A, 
Farahmand BY, Synnerstad I, Boeryd 
B, et al. Effect of pregnancy on survival 
in women with cutaneous malignant 
melanoma. Journal of Clinical 
Oncology. 2004;22(21):4369
[7] Lattanzi M, Lee Y, Simpson D, Moran 
U, Darvishian F, Kim RH, et al. Primary 
melanoma histologic subtype: Impact 
on survival and response to therapy. 
Journal of the National Cancer Institute. 
2019;111(2):180
[8] Chiaravalloti AJ, Jinna S, Kerr PE, 
Whalen J, Grant-Kels JM. A deep look 
into thin melanomas: What’s new for the 
clinician and the impact on the patient. 
International Journal of Women’s 
Dermatology. 2018;4(3):119-121. DOI: 
10.1016/j.ijwd.2018.01.003. ISSN: 
2352-6475
[9] Johansson AL, Andersson TM, 
Plym A, Ullenhag GJ, Møller H, Lambe 
M. Mortality in women with pregnancy-
associated malignant melanoma. 
Journal of the American Academy of 
Dermatology. 2014;71(6):1093-1101. 
Epub: October 16, 2014
[10] Tellez A, Rueda S, Conic RZ, 
Powers K, Galdyn I, Mesinkovska NA, 
et al. Risk factors and outcomes of 
cutaneous melanoma in women less than 
50 years of age. Journal of the American 
Academy of Dermatology. 2016;74(4):731
[11] Møller H, Purushotham A, Linklater 
KM, Garmo H, Holmberg L, Lambe M, 
et al. Recent childbirth is an adverse 
prognostic factor in breast cancer 
and melanoma, but not in Hodgkin 
lymphoma. European Journal of Cancer. 
2013;49(17):3686-3693. Epub: August 6, 
2013
[12] Gachon J, Beaulieu P, Sei JF, 
Gouvernet J, Claudel JP, Lemaitre M, 
et al. First prospective study of the 
recognition process of melanoma in 
dermatological practice. Archives of 
Dermatology. 2005;141(4):434
[13] Brady MS, Noce NS. Pregnancy 
is not detrimental to the melanoma 
patient with clinically localized disease. 
The Journal of Clinical and Aesthetic 
Dermatology. 2010;3:22-28
[14] Vestergaard ME, Macaskill P, 
Holt PE, Menzies SW. Dermoscopy 
compared with naked eye examination 
for the diagnosis of primary melanoma: 
A meta-analysis of studies performed in 
a clinical setting. The British Journal of 
Dermatology. 2008;159(3):669
[15] Stensheim H, Møller B, van Dijk T, 
Fosså SD. Cause-specific survival for 
women diagnosed with cancer during 
pregnancy or lactation: A registry-





[16] Baergen RN, Johnson D, Moore T,  
Benirschke K. Maternal melanoma 
metastatic to the placenta: A case report 
and review of the literature. Archives 
of Pathology & Laboratory Medicine. 
1997;121(5):508
[17] Ignatko IV, Strizhakov AN, 
Protsenko DN, Afanasjeva NV, 
Djadykov IN, Zairatyantz GO, et al. 
Melanoma and pregnancy: Risks, course 
and prognosis. Gynecology, Obstetrics 
and Perinatology. 2018;17(1):83-87. DOI: 
10.20953/1726-1678-2018-1-83-87
[18] Fedorenko IV, Paraiso KHT, 
Smalley KSM. Acquired and intrinsic 
BRAF inhibitor resistance in BRAF 
V600E mutant melanoma. Biochemical 
Pharmacology. 2011;82(3):201-209
[19] Driscoll MS, Grant-Kels JM.  
Hormones, nevi, and melanoma: An 
approach to the patient. Journal of the 
American Academy of Dermatology. 
2007;57(6):919
[20] Vorobiev AV, Makatsaria AD, Bitsadze 
VO, Brenner B. Dysfunction of the 
hemostatic system and carcinogenesis: 
The current state of the matter. Obstetrics 
and Gynecology. 2017;8:28-33. DOI: 
10.18565/aig.2017.8.28-33
[21] Chapman PB, Robert C, Larkin J, 
Haanen JB. Vemurafenib in patients with 
BRAFV600 mutation-positive metastatic 
melanoma: Final overall survival results 
of the randomized BRIM-3 study. Annals 
of Oncology. 2017;28(10):2581-2587. 
DOI: 10.1093/annonc/mdx339
[22] Committee Opinion No. 656. 
Guidelines for diagnostic imaging 
during pregnancy and lactation: 
American College of Obstetricians and 
Gynecologists’ Committee on Obstetric 
Practice. Obstetrics and Gynecology. 
2016;127(2):e75-e80
